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Abstract
Men are at a higher risk of developing bladder cancer than women. Although the urinary bladder is not regarded as an sex 
organ, it has the potential to respond to androgen signals. The mechanisms responsible for the gender differences remain 
unexplained. Androgen receptor (AR) after binding with 5α-dihydrotestosteron (DHT) undergoes a conformational change 
and translocates to nucleus to induce transcriptional regulation of target genes. However androgen/AR signaling can also be 
activated by interacting with several signaling molecules and exert its non-genomic function. The aim of present study was 
to explain whether the progression of bladder cancer in men is dependent on androgen/AR signaling. Studies were carried 
out on human bladder cancer cell lines: HCV29, T24, HT1376 and HTB9. Bladder cancer cells were treated for 48 h with 
10 nM DHT or not, with replacement after 24 h. Expression of cell signaling proteins, was analyzed using Western Blot and 
RT-PCR. Subcellular localization of protein was studied using the ProteoExtract Subcellular Proteome Extraction Kit and 
Western blot analysis. We showed that DHT treatment significantly increased AR expression in bladder cell line HCV29. 
We also observed DHT-mediated activation of Akt/GSK-3β signaling pathway which plays a central role in cancer progres-
sion. Presented results also show that androgen/AR signaling is implicated in phosphorylation of eIF4E which can promote 
epithelial–mesenchymal transition (EMT). We indicate that AR plays an essential role in bladder cancer progression in male 
patients. Therefore, androgen-activated AR signaling is an attractive regulatory target for the inhibition or prevention of 
bladder cancer incidence in men.
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Introduction
Bladder cancer (BC) is currently the one of the very wide-
spread genitourinary tract malignancy, the fifth most com-
mon cancer in men and the nineteenth in women [1, 2]. Dif-
ferent environmental and lifestyle factors, such as industrial 
chemicals or cigarette smoking, have been believed as the 
reasons for sex-related differences. Although the urinary 
bladder is not regarded as an sex organ, it has the poten-
tial to respond to androgen signals, because is derived from 
the endoderm of the urogenital sinus which expresses the 
AR [3]. AR signaling was shown as the crucial oncogenic 
driver of prostate cancer, it is also significantly associated 
with tumor progression in other solid tumors, such as lung, 
kidney, breast and bladder cancers [4, 5]. The mechanisms 
responsible for the gender differences remain unclear but 
AR signaling pathway has been proposed as an important 
factor that is involved in the development and progression of 
BC. Studies in animal models evidence that AR in urothe-
lium may play a crucial role in cancerogenesis and progres-
sion of BC [6]. Shiota et al. showed that men with prostate 
cancer who underwent androgen deprivation therapy had a 
lower risk of development of bladder cancer in comparison 
to those undergoing surgery or radiotherapy, only [7]. Also, 
Fahmy et al. described high incidence of prostatic adeno-
carcinoma in cystoprostatectomy specimens undergone for 
bladder urothelial carcinoma [8].
Androgen receptor in the cytoplasm occurs in the com-
plex with heat shock proteins, and upon binding DHT, AR is 
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released from heat shock proteins and translocates to nucleus 
to induce transcriptional regulation of target genes. This 
AR-signaling pathway is known as the genomic pathway. 
However, androgen/AR signaling can also be activated by 
an alternative mechanism independent on androgen binding 
that includes its phosphorylation by kinases [9, 10]. Studies 
on prostate cancers showed that binding of androgen to AR 
in the cytoplasm may initiate signal transduction pathways to 
regulate cellular proliferation and migration, known as non-
genomic pathway, that requires neither AR nuclear translo-
cation nor DNA binding [11–13]. In addition, non-genomic 
AR signaling may be mediated by a membrane-bound AR 
[14, 15]. Signaling molecules activated by AR in transcrip-
tion-independent manner includes Src, Ras, MAPK, Akt, 
PKC, PLC, EGFR and other secondary messenger proteins 
[15]. It is possible that non-genomic activity influences AR 
genomic activity and that of other nuclear receptor.
Androgen receptor has been detected in human BC in 
a number of studies but it is not clear whether its expres-
sion level is important in bladder cancer progression [9, 
10, 16, 17]. The data suggest that AR expression is more 
often upregulated in early stages of disease than in advanced 
stages of BC [17]. Because men have higher circulating level 
of androgen than females and AR can be variably expressed 
also in female tumors, probably that combination of AR 
expression level and elevated androgen signaling play the 
essential role in gender distinction characterizing BC.
The aim of present study was to elucidate the mechanism 
of androgen/AR signaling in promotion of bladder cancer in 
male patients.
Materials and methods
Cell culture
HCV29 (nonmalignant transitional epithelial cells of the 
ureter), T24 (transitional cancer cells of the urine bladder), 
HT1376 (urinary bladder carcinoma, grade III) and HTB9 
(urinary bladder cancer grade II) cell lines were obtained 
from American Type Culture Collection. These cell lines 
were then purchased from ATCC by M. Lekka’s lab and 
authenticated by short tandem repeat analysis by LGC 
Standard. All cell lines are examined annually for myco-
plasma infection by PCR method. The cells were cultured 
in RPMI-1640 medium supplemented with 10% fetal calf 
serum (FCS) (Gibco) and 1% penicillin/streptomycin [18].
Cell culture treatment
Bladder cancer cells were treated for 48 h with DHT, 10 nM, 
(Sigma-Aldrich) with replacement after 24 h. Dihydrotes-
tosterone was prepared at a stock concentration of 0.2 M in 
ethanol (Sigma-Aldrich). A dose of 10 nM in serum-free 
Opti-MEM (Gibco) was used as the physiological dose capa-
ble of effectively activation of AR expression. As the vehicle 
control, bladder cells were cultured with 0.1% ethanol. Since 
there were no differences between ethanol-treated cells (not 
shown) and untreated cells, the latter were selected as con-
trol cells in each experiment. Bladder cancer cells 24 h after 
seeding were treated for 0.5 h or 1 h with 10 nM DHT, 0.1% 
ethanol as a control in serum-free Opti-MEM and afterwards 
used to study non-nuclear AR signaling.
Preparation of cytoplasmic, membrane, nuclear 
and cytoskeletal cell lysates
Cytoplasmic, membrane, nuclear and cytoskeletal extracts 
were prepared using the  ProteoExtract® Subcellular Pro-
teome Extraction Kit (MERCK Millipore) by following the 
manufacturer’s instructions.
Western blot analysis
Cells lysis and western blot were carried out as previously 
described [18]. Antibodies for: ILK, Akt, E-cadherin, 
Vimentin, GSK-3β, phospho-GSK-3β (Y216), β-catenin 
(all Transduction Laboratories BD), AR, Src, phospho-Src 
(Y416), phospho-ERK (T202/Y204), phospho-Akt (S473), 
phospho-GSK-3β (S9),  D1,  D3 and phospho-eIF4E (S209) 
(all Cell Signaling Technology Inc.), N-cadherin (R&D) 
and β-actin, ZEB1, (all Sigma) SNAIL (ABGENT), Cal-
nexin, HSP-90 (all Calbiochem) were used to detect indi-
cated proteins. The presence of the primary antibody was 
revealed with horseradish peroxidase-conjugated secondary 
antibodies diluted 1:2000 (Cell Signaling Technology Inc) 
and visualized with an enhanced chemiluminescence detec-
tion system (Bio-Rad) as previously described [19]. β-Actin 
served as a loading control. All immunoblots were stripped 
with stripping buffer containing 25 mM glycine–HCl, pH 2, 
1% (wt/v) SDS for 30 min, and incubated in antibody against 
β-actin (dilution, 1:3000; Sigma-Aldrich), which served as 
a loading control. To obtain quantitative results, immunob-
lots were scanned using the public domain ImageJ software 
(National Institute of Health). Each data point was normal-
ized against its corresponding actin data point.
In vitro wound healing/migration assay
The in vitro model of wound healing was used to compare 
the migration and proliferation potential of bladder cancer 
cell lines in presence or absence of DHT. For wound heal-
ing assay, cells were grown in RPMI-1640 medium sup-
plemented with 10% fetal calf serum in 24-well plates until 
confluent. A small linear scratch was created in the conflu-
ent monolayer by gently scraping with sterile 1 ml pipette 
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tip. The cells were washed with medium to remove cellular 
debris and serum-free Opti-MEM media with 10 nM DHT 
or 0.01% ethanol as control were added. Twenty-four hours 
later, images of the migrated cells were taken using digi-
tal camera (Nikon), connected to the inverted microscope. 
The assay was repeated thrice in duplicate. Wound area was 
calculated by manually tracing the cell-free area in cap-
tured images using the public domain ImageJ software. The 
migration rate was expressed as the percentage of wound 
closure.
RNA extraction, cDNA synthesis and RT‑PCR analysis
RNA extraction, preparation of cDNA and RT-PCR reaction 
were carried out as previously described [18]. The following 
specific primers were used:
GAPDH; (59 °C, 30 s): 5′CAC CGC CTC GGC TTG TCA 
CAT 3′ and 5′CTG CTG TCT TGG GTG CAT TGC3′;
N-CADHERIN; (60 °C, 40 s): 5′GTG CCA TTA GCC AAG 
GGA ATT CAG C3′ and 5′CGA GGA TAC TCA CCT TGT CCT 
TGC G 3′;
E-CADHERIN; (60 °C, 40 s): 5′GCC AAG CAG CAG TAC 
ATT CTA CAC G3′ and 5′GTC GTT CTT CAC GTG CTC AAA 
ATC C3′;
AR; (58, 30 s): 5′ TGT CAA CTC CAG GAT GCT CTA CTT 
3′ and 5′ATT CGG ACA CAC TGG CTG TACA3′
The PCR reaction products were separated electropho-
retically on 2% agarose gel and visualized with ethidium 
bromide.
Statistical analysis
Each variable was tested using the Shapiro–Wilk W test for 
normality. Homogeneity of variance was assessed with Lev-
ene’s test. Since the distribution of the variables was normal 
and the values were homogeneous in variance, all statistical 
analyses were performed using one-way analysis of vari-
ance (ANOVA) followed by Dunnett’s post hoc comparison 
test to determine which values differed significantly from 
controls. The analysis was made using Statistica software 
(StatSoft). Data were presented as mean ± SD. Data were 
considered statistically significant at p* < 0.05, p** < 0.01, 
p*** < 0.001.
Results
Expression of AR in human bladder and cancer cell 
lines
Urinary bladder cancer cell lines are very important research 
tools for studying biological and molecular mechanisms in 
cancer progression. Cell lines T24, HTB9 and HT1376 are 
described as representative models for study of human uri-
nary bladder carcinogenesis because those lines cover the 
more frequent subtypes of this kind of tumor, representing 
a less aggressive phenotype and the later bearing more inva-
sive and metastatic properties [20, 21]. Additionally, HCV29 
as nonmalignant transitional epithelial cells of the ureter is a 
commonly treated as right reference, non-cancerous cell line 
in this model. We investigated the expression of androgen 
receptor in human bladder cancer cell lines T24, HTB9, and 
HT1376 as well as a nonmalignant transitional epithelial 
cells of the ureter HCV29 by Western blotting (Fig. 1).
AR expression was found to be the strongest in the tran-
sitional epithelial cells HCV29 and in transitional cell car-
cinoma T24. Both cell lines have been derived from men 
as well as more aggressive cell line HTB9 from grade II. 
The expression of AR was not found in HTB9 and in cell 
line HT1376 from grade III carcinoma, which is of female 
origin. These results suggested that AR expression is higher 
in non-cancer stage and in the early stages of bladder cancer 
progression, and likely decreases as the disease progresses.
Effects of DHT on androgen receptor expression 
in bladder cell lines
We assessed changes in androgen receptor expression on 
protein level following 10 nM DHT treatment in bladder cell 
lines in comparison to control condition by Western blot. 
As shown Figs. 2 and 3, DHT treatment for 48 h increased 
significantly (4.7-fold) AR expression in nonmalignant tran-
sitional epithelial cells of the urether HCV29. In bladder 
cancer cell lines AR expression was marginally upregulated 
(1.2-fold) only in transitional cancer cell line T24 (Figs. 2, 
3). These results suggest that androgen can directly stimulate 
the expression of its own receptor, especially at the early 
stages of cancer initiation.
Non‑nuclear AR signaling
Androgen receptor non-genomic action originates in the 
cytoplasm or at the plasma membrane. Signaling molecules 
activated by AR include Src family, MAPK, PKC, Akt and 
other second messenger proteins. We examined whether 
androgen stimulation led to expression and activation of Src, 
Erk and Akt signaling pathways. Expression of activated 
molecules was monitored by phospho-specific antibodies. 
The increase of Akt phosphorylation was visible after 0.5 h 
treatment with DHT in both cell lines. The highest increase 
was observed after 0.5 h for T24 and after 1 h for HCV 
29 and was still high after 48 h compared to the control. 
A rapid response after 1 h DHT treatment, was, however, 
detected also in cell lines HTB9 and HT1376, which did not 
express the classical AR, but in longer time 48 h, the effect 
was reduced in comparison to control cells (Fig. 2). The 
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results indicated that androgen/AR interaction activates sig-
nificantly Akt throughout the increase (2.3-fold) of its phos-
phorylation on Ser 473 at early stage of cancer cell line T24 
and in nonmalignant transitional epithelial cell line HCV29 
(1.86-fold) with slight difference in total Akt expression 
after 48 h (Fig. 3a). Upon activation, Akt phosphorylate a 
lot of other proteins including glycogen synthetase kinase 3 
(GSK3). GSK-3β kinase activity is inhibited by direct phos-
phorylation at Ser 9 by Akt. DHT supplementation was suf-
ficient for meaningful increase of phosphorylation of Ser 9 
GSK-3β. Because the key proteins regulated by GSK-3β are 
β-catenin, we next examined the relationship between the 
higher phosphorylation of Ser 9 GSK-3β and the levels of 
total β-catenin and its nuclear accumulation. We detected 
increased total levels of β-catenin only in HCV29 cell line 
(Fig. 3a) but we did not observe any differences in nuclear 
translocation of β-catenin after DHT treatment in both tested 
cell lines (Fig. 4). We did not notice activation of the remain-
ing tested kinases (Src and ERK1/2) (Fig. 3a) as well as we 
did not see any activation of Akt in more aggressive cell 
lines HTB9 and HT1376 9 (Fig. 3b).
Androgen mediates AR translocation
Androgen receptor usually locates in cytoplasm in complex 
with heat shock protein. Ligand-activated AR is known 
to translocate to the nucleus and subsequently activates 
transcription of several target genes. Cytoskeletal proteins 
facilitate nuclear targeting of AR. We checked intracellular 
localization of AR in the presence and absence of DHT. 
Western blot analysis of subcellular fraction (Fig. 4) shown 
that, without ligand, AR is located largely in the cytoplasm, 
but after incubation with DHT, AR is still present in cyto-
plasm but also undergoes preferentially to cytoskeletal frac-
tion and membrane fraction and small amount are present in 
nucleus. These results suggest that DHT in bladder cancer 
activates not only the canonical AR signaling but also the 
non-genomic AR signaling.
AR and Akt interact in lipid rafts in membrane 
fraction
Androgen receptor non-genomic signaling pathway can start 
as well at the plasma membrane. AR associates with plasma 
membrane lipid rafts and facilitates AR activation of these 
pathways. AR can localize to lipid rafts and interacts with 
and activate Akt independently of PI3K, which is usually 
required for downstream activation of Akt. Western blot 
analysis of subcellular fraction has shown visible increase 
of Akt level likewise AR protein in membrane fraction 
after androgen stimulation in comparison to control non-
stimulated cells in both bladder cell lines HCV29 and T24 
(Fig. 4).
Androgen/AR signaling modulates translation 
initiation
Cancer cells require elevated level of protein synthesis and 
translational control is critical for maintaining protein level. 
The majority of mRNA is translated by the cap-dependent 
Fig. 1  Expression of AR in HTB 9, HT1376, T24 and HCV29 blad-
der cell lines after 48  h treatment with 10  nM DHT. a AR expres-
sion on mRNA level was determined by reverse transcription-PCR. 
As an intrinsic control, the GAPDH mRNA level was measured in the 
samples. The relative level of each mRNA normalized against its cor-
responding GAPDH and expressed as relative optical density. Data 
obtained from three separate analyses are expressed as mean ± SD. b 
Protein expression was analyzed by Western blot. Total protein load-
ing was determined by probing the membranes for β-actin. The rela-
tive level of each protein normalized against its corresponding β-actin 
and expressed as relative optical density. Data obtained from three 
separate analyses are expressed as mean ± SD
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mechanism. The increased level of free eukaryotic initia-
tion factor 4E (eIF4E) and phosphorylated eIF4E can pro-
mote activation of cap-dependent translation. Housekeeping 
mRNAs require a low level of eIF4E, whereas proto-onco-
genic and prosurvival proteins have a much higher depend-
ency on phosphorylated eIF4E for translation. The increase 
of phosphorylated eIF4E promotes EMT and metastasis 
in cancer. We found that phosphorylation of eIF4E was 
increased after DHT stimulated androgen signaling, but we 
did not observe changes in cap-dependent translational con-
trol of cyclins  D1 and  D3 expression (Fig. 5).
Effect of AR on EMT markers in bladder
Epithelial mesenchymal transition accompanies transforma-
tion from a quiescent cancer cells to a malignant phenotype. 
Loss of E-cadherin expression and induction of N-cadherin 
expression is a hallmark of the EMT process. Androgen-
mediated AR signaling can induce EMT. Studied bladder 
cell lines: HCV29 and T24 express both E- and N-cadherins. 
HCV29 expresses comparable level of both E- and N-cad-
herins, but T24 expresses N-cadherin and a little E-cadherin 
at the protein and mRNA level (Fig. 6). We checked whether 
the AR signaling pathway might contribute to cadherin 
switch in bladder cell lines. As shown in Fig. 6, 48-h DHT 
stimulation was sufficient to downregulate the expression of 
E-cadherin in both cell types, and increase the expression of 
N-cadherin. As shown in Fig. 6 the expression of genes of 
a family of transcriptional factors including Snail and Zeb 
remains unchanged after androgen treatment, similarly like 
activity of metalloproteinases (data not shown).
AR influences would healing
Cell migration and proliferation determine the rate of 
wound healing. Scratch wound healing assays were per-
formed to evaluate the effects of DHT on bladder cells’ 
migration/proliferation. The results demonstrated that 
Fig. 2  The effect of androgen (10  nM DHT) treatment of bladder 
cells on androgen receptor expression and Akt activation in non-
genomic action of AR in 0.5 h; 1 h and 48 h incubation. Densitom-
etry was used to normalize AR to β-actin protein level, and phospho-
rylated Akt to total Akt and to β-actin protein level. Presented are 
representative membranes of at least three independent experiments 
with similar results
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Fig. 3  The effect of androgen 
(10 nM DHT) treatment of blad-
der cells on androgen receptor 
expression and action of AR 
on downstream signaling target 
proteins after 48 h incubation. a 
The effect of DHT treatment of 
transitional cells: HCV29 and 
T24. b The effect of DHT treat-
ment of aggressive bladder cell 
lines HTB9 and HT1376. Den-
sitometry was used to normalize 
to β-actin protein level and for 
quantitative comparison after 
DHT treatment. Presented are 
representative membranes of at 
least three independent experi-
ments with similar results
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androgen treatment significantly accelerated wound clo-
sure after 24 h in transitional cell carcinoma T24 and in 
the transitional epithelial cells HCV29. We observed a 
slight supporting effect of DHT treatment on wound heal-
ing in HTB9 derived from men as more aggressive cell 
line, however the effect was invisible in HT1376 from 
grade III carcinoma, which is of female origin (Fig. 7).
Discussion
Both genetic and environmental factors contribute to the 
initiation, progression and development of urinary blad-
der cancer (UBC). Using molecular classification in blad-
der cancer cell line models, we recognized that bladder cell 
lines showed differential expression of androgen receptor in 
male origins cell lines and responded differently to andro-
gen stimulation. We found that nonmalignant transitional 
epithelial cells and transitional cell carcinoma had higher 
levels of AR expression compared to high-grade or muscle-
invasive tumor cell lines. Also, immunohistochemistry study 
by Miyamoto et al. or Boorjian and colleagues indicated 
that down-regulated AR expression in UBC may be associ-
ated with tumor progression [22, 23]. However, other studies 
presented conflicting data [24]. Additionally, we observed 
very significant increase in androgen protein level after sup-
plementation of DHT only in nonmalignant and carcinoma 
transitional cells. Androgens are known important regulators 
of AR mRNA and protein through transcriptional and post-
transcriptional mechanisms. AR is ligand-dependent tran-
scriptional factor that regulates gene expression, ligand bind-
ing profoundly increases AR stability and this stabilization 
is relatively unique to AR as other steroid receptors undergo 
hormone-mediated downregulation [25]. AR increases more 
than three times in the presence of androgen in prostate cell 
Fig. 4  Androgen-dependent cellular localization of AR, Akt or 
β-catenin. Cytoplasmic (C), nuclear (N), membrane (M) and 
cytoskeleton (S) proteins were extracted as described in Materials and 
Methods. Calnexin, HSP 90 and vimentin were used as marker pro-
teins specific for the appropriate fraction. Data were obtained from 
triplicate experiments
Fig. 5  DHT treatment modulates translation by the cap-dependent 
mechanism. Densitometry was used to normalize to β-actin protein 
level and for quantitative comparison after DHT treatment
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line LNCaP. The half-life of ligand-bound AR protein lev-
els is also sensitive to regulation by cap-dependent mRNA 
translation [26]. Mikkonen et al. have shown that androgen 
administration significantly upregulated AR expression in 
murine lung and modified gene expression in a human lung 
cancer cell line [4]. Higher level of androgens in men than in 
women may be a reason for increased AR protein level and 
intensification of AR signaling especially at early stages of 
tumor initiation and progression of BC. After androgen stim-
ulation in both cell lines HCV29 and T24, we observed AR 
translocation to the nucleus and also increased AR amount 
in cytoskeletal fraction. Interaction of AR with cytoskeletal 
proteins facilitates nuclear targeting of AR and probably 
increased of AR transcriptional activity which plays impor-
tant role in  G1/S phase transition. The cytoplasmic action of 
AR is observed also in non-prostate cells, such as fibroblast, 
where the level of AR is relatively low, and AR translocation 
in response to androgen is not observed [10]. However, non-
genomic AR signaling also promotes cell proliferation and 
survival. Activation of AR signaling causes the regulation 
of numerous signaling pathways PI3K/Akt, Src and MAPK/
ERK that in turn regulate cell proliferation. In addition, non-
genomic effects of DHT can manifest independently, or in 
tandem, with the other genomic effects, to initiate androgen 
responses.
We showed that androgen stimulation of bladder non-
malignant and cancer cells resulted in the activation of 
the PI3K/Akt pathway. Upon ligand binding AR interacts 
directly with the p85α regulatory subunit of PI3K, result-
ing in phosphorylation of Akt. We observed the increased 
phosphorylation of downstream signaling target protein 
kinases Akt and glycogen synthase kinase-3β (GSK-3β), 
whereas the levels of Akt and GSK-3β protein remained 
almost unchanged. Cinar et al. proved that AR upon binding 
DHT can activate Akt kinase in lipid rafts and mediates non-
genomic signaling independent of PI3K [14]. Data suggest 
that AR associates with plasma membrane that facilitates 
activation of these pathways. The molecular mechanism 
controlling recruitment of AR to the plasma membrane is 
unclear. We also noticed the increase of AR level in plasma 
membrane fraction and this was accompanied by increase of 
Akt in this same fraction (Fig. 8). Interestingly, not all cell 
types that demonstrate a rapid androgen response express 
the classical nuclear AR. In the literature, the observation 
of non-genomic androgen-mediated activation of signaling 
pathways occur through different mechanisms in different 
cell types [27]. However, cytoplasmic AR signaling may also 
function through mitogen-activated protein kinase (MAPK) 
signaling, converging on extracellular signal regulated 
kinase (ERK) activation [28]. Another well-studied signal-
ing molecule activated by steroid receptors is Src. In addi-
tion Src may also activate Erk 1/2 signaling cascade but we 
did not observe changes in phosphorylation level of Erk1/2 
or any increase of Src kinase activation. Src activated by AR, 
can also stimulate proliferation and survival of prostate cells 
by enhanced PI3K signaling pathway. Non-genomic signals 
from AR to Akt may omit both PI3K and Src. Our data indi-
cated that DHT-mediated AR-dependent Akt phosphoryla-
tion involved PI3K or is a result of direct interaction of Akt 
and AR in bladder cell lines. It is well known that Akt plays 
central role in cancer progression. This critical pathway acts 
as a convergence point for a multitude of upstream signals 
and in turn stimulates the activity of numerous downstream 
effectors, thereby mediating enhanced cellular survival, 
growth, protein synthesis, motility, and other functions of 
protumorigenic impact [29]. Accordingly, it is not surpris-
ing that deregulation and aberrant activation of the PI3K/
Akt signaling pathway are common molecular events in a 
Fig. 6  Effect of AR on EMT markers in transitional bladder cells. a 
E-cadherin, N-cadherin expressions on mRNA level were determined 
by reverse transcription-PCR 48 h after 10 nM DHT treatment. Den-
sitometry was used to normalize to GAPDH level and for quantitative 
comparison after DHT treatment. b EMT markers on protein level. 
Densitometry was used to normalize to β-actin protein level and for 
quantitative comparison after DHT treatment. Representative results 
of at least three independent experiments are presented
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Fig. 7  The effect of androgen (10  nM DHT) treatment on in  vitro 
wound healing/migration assay. Data from at least four separate anal-
yses were expressed as mean ± SD. Asterisks show significant dif-
ferences between migration rate of control and DHT-treatment cells. 
Values are denoted as *p < 0.05 and ***p < 0.001
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wide range of malignancies. Additionally, DHT-mediated 
activation of Akt is AR dependent in bladder cancer. Our 
results indicate that non-genomic signals involving AR in 
bladder cancer likely diverge at the level of cytoplasmic 
and plasma membranes. It is possible that AR non-genomic 
activity ultimately serves to influence AR genomic activ-
ity, because AR-activated kinase Akt can phosphorylate 
and activate AR in autocrine positive feedback loop [11]. 
Miyamoto and colleagues documented that AR involving 
genomic or non-genomic signals can also induce bladder 
tumor [30]. They showed that ARKO (AR knockout) mice 
do not get chemically induced bladder carcinogenesis, but 
when ARKO mice were supplemented with DHT, 25% of 
them developed bladder tumors. The ARKO mice were 
generated by a disruption of exon 2 of the AR gene, which 
encodes the AR DNA-binding domain. They provided the 
first in vivo evidence that AR in urothelium might play a 
crucial role in initiation and progression of urinary bladder 
cancers in genomic and non-genomic way. In addition AR 
inhibition attenuates tumor growth of T24 xenografts [31].
Activation of AR causes the regulation of numerous sign-
aling pathways that in turn regulate EMT, which is early 
step in metastatic progression. EMT is a process by which 
epithelial cells lose their epithelial features and obtain a 
mesenchymal phenotype. Loss of E-cadherin expression and 
induction of N-cadherin expression is a hallmark of the EMT 
process [32]. A reduction or loss in expression of E-cadherin 
and the increase of N-cadherin expression in bladder can-
cer have been shown to be important in cancer progression 
[33]. Androgen-mediated AR signaling was also described 
to induce EMT in bladder cancer cells [34, 35]. Our data 
demonstrate that AR signaling can regulate the “cadherin 
switch” in bladder nonmalignant transitional epithelial cells 
and cancer cells. Robichaud et al. reported that EMT is regu-
lated also by cap-dependent translation in mammary tumor 
model. They showed that eIF4E phosphorylation on Ser 209 
is important for EMT and invasion [36]. It is also known that 
eIF4E activity is essential for controlling proliferation and 
invasion in bladder cancer [37]. Availability and phospho-
rylation of eIF4E are regulated by various upstream kinases 
and one of them is Akt. In our study, we found the slight 
increase of phosphorylation of eIF4E after DHT stimulation 
of androgen signaling. Considering how important factor 
is translational control in tumorigenesis, our result is not 
without significance.
It has been suggested that muscle-invasive bladder can-
cers are initially androgen sensitive for their growth but the 
sensitivity is lost during the progression due to activation of 
set of genes involved in metastasis. Activation of androgen/
AR genomic and non-genomic signaling probably is not a 
driver in male bladder oncogenic transformation, but is a 
major player in progression of those cancers. Therefore, 
androgen-activated AR signaling is an attractive regulatory 
target for the inhibition or prevention of bladder cancer inci-
dence in men.
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Fig. 8  Model of the signaling pathway active in effect of DHT treat-
ment in bladder cells. DHT interacts with AR, and translocates to 
nucleus to elicit transcriptional regulation of target gene. Note that 
DHT also stimulates activation of Akt kinase pathway. Akt kinase, 
after binding to plasma membrane is activated and stimulate AR/
DHT complex to nucleus or/and regulate GSK-3β activity via its 
phosphorylation
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